QRxPharma Ltd.  

(Public, ASX:QRX)   Watch this stock  
Find more results for QRX
0.700
0.000 (0.00%)
Apr 17 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.68 - 0.72
52 week 0.58 - 1.34
Open 0.71
Vol / Avg. 307,142.00/218,785.00
Mkt cap 114.88M
P/E     -
Div/yield     -
EPS -0.07
Shares 164.12M
Beta     -
Inst. own     -
Mar 11, 2014
QRxPharma Ltd at EBD BIO-Europe Spring
Feb 25, 2014
Interim 2014 QRxPharma Ltd Earnings Release
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -827.74% -247.91%
Operating margin -882.10% -262.59%
EBITD margin - -264.71%
Return on average assets -67.16% -53.85%
Return on average equity -78.00% -71.60%
CDP Score - -

Address

Level 1, 194 Miller Street
NORTH SYDNEY, NSW 2060
Australia
+61-2-94928021 (Phone)
+61-2-89200314 (Fax)

Website links

Description

QRxPharma Limited is a commercial-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management. The Company�s complementary pain management product formulations- in both early and late stage clinical development, which include: MOXDUO IR, an immediate release oral capsule for acute pain; MOXDUO CR, a controlled release oral tablet chronic pain; and MOXDUO IV, an intravenous formulation for moderate to severe hospital-based pain. The Company is developing Dual Opioid formulation for treating patients with moderate to server acute or chronic pain. The Company�s Dual Opioid portfolio includes three complementary products: Q8003, an immediate-release oral capsule for acute pain; Q8011, a controlled-release oral tablet (with abuse deterrent and tamper resistant features) for chronic pain; Q8012, an intravenous formulation for moderate to severe pain secondary to hospital based procedures.

Officers and directors

John W. Holaday Ph.D. Chief Executive Officer, Managing Director, Executive Director
Chris J. Campbell Chief Financial Officer, Company Secretary
Edward M. Rudnic Ph.D. Chief Operating Officer
M. Janette Dixon Vice President - Global Business Development
Peter C. Farrell Ph.D. Non-Executive Chairman of the Board
Age: 71
R. Peter Campbell Non-Executive Director
Gary W. Pace Ph.D. Non-Executive Director
Age: 65
Michael A. Quinn Non-Executive Director
Age: 65